Eli Lilly and Company (NYSE: LLY) has announced a significant investment of USD 5.3 billion aimed at boosting its manufacturing capacity for incretin receptor agonists Zepbound (tirzepatide) and Mounjaro (tirzepatide). This initiative involves the expansion of an active pharmaceutical ingredients (APIs) manufacturing facility in the United States. With this investment, Eli Lilly has now committed over USD 18 billion to its manufacturing sites since 2020, a period during which the company began achieving promising clinical results for tirzepatide.
The construction of the new facilities is anticipated to be completed by 2026, with the scale-up of operations continuing through 2028.- Flcube.com
